Dr. Emil Khisamutdinov's lab focuses on creating innovative alternatives to traditional monoclonal antibodies using nucleic acid technology. By developing nanoparticles that mimic antibodies, the lab aims to improve detection and treatment methods for prostate cancer while reducing production costs and overcoming some limitations of existing therapies. The research integrates engineering with molecular biology to design stable, programmable materials that could revolutionize therapeutic approaches in cancer treatment.